Market Cap (In SEK)
14.18 Million
Revenue (In SEK)
2.63 Million
Net Income (In SEK)
-11.11 Million
Avg. Volume
12.97 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.13-14.9
- PE
- -
- EPS
- -
- Beta Value
- 0.01
- ISIN
- SE0022447173
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Mikael Lindstam
- Employee Count
- -
- Website
- https://www.aptahem.com
- Ipo Date
- 2015-04-17
- Details
- Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
More Stocks
-
CLEU
-
8623
-
3825Remixpoint, Inc.
3825
-
300832
-
CENTRCentric Holdings S.A.
CENTR
-
DKSHDKSH Holding AG
DKSH
-
5297
-
0732